Lung cancer continues to have a poor prognosis in most patients, which can be attributed to the ineffective delivery of drugs to the lung tissue with standard therapies. Inhaled delivery of pharmaceuticals is an approach that circumvents the shortcomings of standard intravenous (IV) delivery, but prior attempts have had issues either reaching the lungs or with treatment exhalation after initial delivery.

However, an innovative excipient-enhanced growth (EEG) platform for inhalation drug delivery offers a mechanism to overcome previous issues and high feasibility for transporting a promising therapeutic agent, gemcitabine, directly into the lungs of cancer patients. EEG allows for highly targeted drug delivery into the lungs and can be robustly manufactured via a spray-drying particle engineering method. This dry-powder inhalation platform can be flexibly scaled according to manufacturers’ needs and is appealing for a variety of inhalation-based therapies. 

Read the executive summary to discover more on how innovation excipient-enhanced growth formulation can be scaled up readily with conventional spray-drying after minimal medication to standard processes.

You may also be interested in:
By clicking "Access Content" you agree to our Legal Disclaimer and the Lonza Privacy and Cookies Policy.

Latest content
Latest briefing from the Knowledge Center